BRC
Blue Ridge Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-1,338,300
| Closed | -$170M | – | 2 |
|
|
2017
Q4 | $170M | Sell |
1,338,300
-193,599
| -13% | -$24.6M | 5.66% | 6 |
|
|
2017
Q3 | $180M | Buy |
1,531,899
+155,199
| +11% | +$18.2M | 3.23% | 15 |
|
|
2017
Q2 | $110M | Sell |
1,376,700
-213,300
| -13% | -$17M | 1.92% | 23 |
|
|
2017
Q1 | $81.5M | Buy |
1,590,000
+270,000
| +20% | +$13.8M | 1.06% | 32 |
|
|
2016
Q4 | $49.4M | Hold |
1,320,000
| – | – | 0.62% | 39 |
|
|
2016
Q3 | $89.5M | Hold |
1,320,000
| – | – | 1.06% | 33 |
|
|
2016
Q2 | $73.2M | Buy |
1,320,000
+245,000
| +23% | +$13.6M | 0.95% | 34 |
|
|
2016
Q1 | $67.5M | Hold |
1,075,000
| – | – | 0.82% | 36 |
|
|
2015
Q4 | $101M | Hold |
1,075,000
| – | – | 1.13% | 36 |
|
|
2015
Q3 | $86.4M | Hold |
1,075,000
| – | – | 0.99% | 40 |
|
|
2015
Q2 | $129M | Buy |
1,075,000
+115,000
| +12% | +$13.8M | 1.45% | 35 |
|
|
2015
Q1 | $100M | Buy |
960,000
+530,000
| +123% | +$55.3M | 1.14% | 34 |
|
|
2014
Q4 | $41.7M | Buy |
+430,000
| New | +$41.7M | 0.51% | 41 |
|